S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

CRVO CervoMed Inc

2.33

0.00 (0.00%)

Pre Market

Last Updated: 06:00:00

Delayed by 15 minutes

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

CervoMed (NASDAQ:CRVO)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more CervoMed Charts.

CervoMed (NASDAQ:CRVO)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more CervoMed Charts.

CervoMed Inc News

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 14 February 2025 (4 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 14 February 2025 (4 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 14 February 2025 (4 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 14 February 2025 (4 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 14 February 2025 (4 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 31 January 2025 (3 weeks ago) • Edgar (US Regulatory)

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
Friday 31 January 2025 (3 weeks ago) • GlobeNewswire Inc.

CervoMed to Present at the 8th International Lewy Body Dementia Conference
Wednesday 29 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Monday 13 January 2025 (1 month ago) • Edgar (US Regulatory)

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Thursday 12 December 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 10 December 2024 (2 months ago) • Edgar (US Regulatory)

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
Tuesday 10 December 2024 (2 months ago) • GlobeNewswire Inc.

More CervoMed Inc News Articles

BNP Paribas Issuance

Societe Generale Effekten

Invesco S&P 500 UCITS ET...

Societe Generale Effekten

Societe Generale Effekten

HSBC Emerging Market Sus...

iShares Global Tech

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions